This is the authors' abstract. We don't add key points for this paper.
Adolescent retroperitoneal sarcoma (RPS) poses significant decision-making challenges due to complex subtypes and limited molecular diagnosis. A 16-year-old male with a 13.8 cm retroperitoneal mass underwent R0 en bloc resection (with left adrenal gland). Pathology favored high-grade fibrosarcoma. He completed 5 cycles of adjuvant Ifosfamide and Doxorubicin. At 17 months post-surgery, surveillance shows no disease recurrence. When molecular testing is unavailable for large, high-grade adolescent RPS, combining R0 en bloc resection with intensive adjuvant chemotherapy remains an effective strategy for favorable outcomes.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: